stockrow
Saturday 7 November 2026
Export VERU’s income statement to Excel — free account
Veru Inc.
VERU Healthcare Biotechnology
Veru Inc.’s revenue for fiscal 2024 (year ended September 2024) was $16.9 million, up 3.62% from fiscal 2023.
- EPS
- +40.0%
- Free cash flow
- +0.27%
Quarter to June 2026, against a year earlier
2.14
0.08
+3.88%
Follow VERU
Alert me
Veru Inc. (VERU) P/E ratio
Veru Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1,039× (February 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 65.6× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 109× | 932.29% |
| FY2015 | 10.5× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| 35 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1,039×
Ten-year median
0.0×
Current reading's percentile
77
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VERU Veru Inc. | n/m |
| PTHS Pelthos Therapeutics Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| GRDX GridAI Technologies Corp. compare | n/m |
| NNVC NanoViricides, Inc. compare | n/m |
| GRCE Grace Therapeutics, Inc. compare | n/m |
| PMN Promis Neurosciences compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| LIANY LianBio Sponsored ADR compare | 0.0× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)